Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 8

Emerging Data of Additional SERDs in Metastatic Breast Cancer

Panelists discuss recent data on other selective estrogen receptor degraders (SERDs) and their implications in the treatment of HR+/HER2– breast cancer.

Video content above is prompted by the following:

Dr. Bardia to Dr. Teplinsky: Please briefly mention recent data on other SERDs: